Navigation Links
Sangui Bio Tech International Inc. Shareholders' Meeting Delayed to Include FY 2008 Report
Date:9/17/2008

WITTEN, Germany, September 17 /PRNewswire/ -- Sangui BioTech International, Inc., is currently preparing its financial statements for its 2008 financial year (ended June 30, 2008). The ensuing report on form 10KSB will be filed with the SEC and made public in due course. It will be included in the proxy materials for the forthcoming annual shareholders' meeting. This was also requested in a letter by the SEC. Subsequently, the shareholders' meeting will be delayed by a few weeks. Shareholders will be informed about the new schedule immediately after the pertaining resolutions will have been passed by the Board of directors.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-(160)-741-27-17

Fax: +49-(2302)-915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangui BioTech International, Inc. Files Remaining Reports
2. Investors Acquire Share in Sangui BioTech GmbH
3. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
4. Sangui Partnership Enters a New Phase:
5. China Yingxia International, Inc. Appoints New Vice President of Finance
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
8. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
9. Singapore to hold international pow-wow
10. Mindray Medical International Announces Second Quarter 2008 Results
11. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... Parallel6™ ... clinical trials worldwide, announced today that they were named one of the 2017 ... covers the latest developments in the pharmaceutical industry. , “We take pride in honoring ...
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention to Biotechnology, ... research aimed at treating diseases and medical conditions. Under evaluation ... (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology ... complimentary research reports on these stocks now at: ... http://stock-callers.com/registration Biostage ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of ... accessible to novices as well as experienced users, attendees will gain a better ... screening tests. , Hemostasis testing quality is determined by preanalytical variables which ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):